MD Stock Analysis: Mednax | NYSE
Medical Care Facilities | NYSE, USA | Market Cap: 2.107m USD | 12M Return: 61% | US58502B1061 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.5M
EPS Trend: 91.6%
Qual. Beats: 0
Rev. Trend: -82.7%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Pediatrix Medical Group (formerly MEDNAX) is a U.S. health care services company that provides newborn, maternal-fetal, and pediatric subspecialty care. Its clinical offerings are delivered through a national network of affiliated physicians, nurse practitioners, midwives, sonographers, and other clinicians serving patients primarily in hospital settings such as neonatal intensive care units (NICUs), obstetrics units, and pediatric departments. The company also supports newborn hearing screening and related ancillary services. Founded in 1979 and headquartered in Sunrise, Florida, Pediatrix adopted its current name in July 2022.
The company operates on an affiliated-physician model, in which independent neonatal and maternal-fetal specialists contract with the group to deliver hospital-based clinical care, a structure that is common among U.S. physician practice management organizations. As a small-cap health care services provider listed on the NYSE under the ticker MD, Pediatrix generates revenue primarily through professional services billing for physician and clinician work performed in inpatient and outpatient settings.
- U.S. birth rate decline pressures NICU patient volumes
- Medicaid reimbursement changes impact NICU profit margins
- Anesthesia segment sale refocuses capital on core pediatrics
| Net Income: 174.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.05 > 1.0 |
| NWC/Revenue: 8.13% < 20% (prev 14.02%; Δ -5.89% < -1%) |
| CFO/TA 0.12 > 3% & CFO 247.2m > Net Income 174.8m |
| Net Debt (251.5m) to EBITDA (267.0m): 0.94 < 3 |
| Current Ratio: 1.32 > 1.5 & < 3 |
| Outstanding Shares: last quarter (81.4m) vs 12m ago -6.27% < -2% |
| Gross Margin: 25.95% > 18% (prev 24.36%; Δ 1.59% > 0.5%) |
| Asset Turnover: 92.17% > 50% (prev 92.32%; Δ -0.15% > 0%) |
| Interest Coverage Ratio: 8.64 > 6 (EBIT TTM 244.0m / Interest Expense TTM 28.2m) |
| A: 0.07 (Total Current Assets 660.1m - Total Current Liabilities 501.6m) / Total Assets 2.13b |
| B: -0.01 (Retained Earnings -13.7m / Total Assets 2.13b) |
| C: 0.12 (EBIT TTM 244.0m / Avg Total Assets 2.12b) |
| D: 0.71 (Book Value of Equity 881.0m / Total Liabilities 1.25b) |
| Altman-Z'' = 1.98 = BBB |
| DSRI: 0.96 (Receivables 239.0m/246.6m, Revenue 1.95b/1.94b) |
| GMI: 0.94 (GM 24.36% / 25.95%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.67) |
| SGI: 1.01 (Revenue 1.95b / 1.94b) |
| TATA: -0.03 (NI 174.8m - CFO 247.2m) / TA 2.13b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of September 28, 2026, the stock is trading at USD 26.31 with a total of 386,017 shares traded. Over the past week, the price has changed by +1.47%, over one month by -2.52%, over three months by +9.12% and over the past year by +61.02%.
Current recommended Stop Loss: 24.50 (which is 6.9% or 2.1 ATR below the current price).
Mednax has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold MD.
- StrongBuy: 3
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 26.3 | 0.1% |
P/E Trailing = 12.1737
P/E Forward = 9.2937
P/S = 1.0801
P/B = 2.351
P/EG = 0.2433
Revenue TTM = 1.95b USD
EBIT TTM = 244.0m USD
EBITDA TTM = 267.0m USD
Long Term Debt = 398.1m USD (from longTermDebt, last quarter)
Short Term Debt = 198.4m USD (from shortTermDebt, last quarter)
Debt = 655.7m USD (from shortLongTermDebtTotal, last quarter) + Leases 35.7m
Net Debt = 251.5m USD (calculated: Debt 655.7m - CCE 404.2m)
Enterprise Value = 2.36b USD (2.11b + Debt 655.7m - CCE 404.2m)
Interest Coverage Ratio = 8.64 (Ebit TTM 244.0m / Interest Expense TTM 28.2m)
EV/FCF = 10.30x (Enterprise Value 2.36b / FCF TTM 229.0m)
FCF Yield = 9.71% (FCF TTM 229.0m / Enterprise Value 2.36b)
FCF Margin = 11.74% (FCF TTM 229.0m / Revenue TTM 1.95b)
Net Margin = 8.96% (Net Income TTM 174.8m / Revenue TTM 1.95b)
Gross Margin = 25.95% ((Revenue TTM 1.95b - Cost of Revenue TTM 1.44b) / Revenue TTM)
Gross Margin QoQ = 27.16% (prev 23.72%)
Tobins Q-Ratio = 1.11 (Enterprise Value 2.36b / Total Assets 2.13b)
Interest Expense / Debt = 4.31% (Interest Expense 28.2m / Debt 655.7m)
Taxrate = 22.73% (51.4m / 226.2m)
NOPAT = 188.5m (EBIT 244.0m * (1 - 22.73%))
Current Ratio = 1.32 (Total Current Assets 660.1m / Total Current Liabilities 501.6m)
Debt / Equity = 0.74 (Debt 655.7m / totalStockholderEquity, last quarter 881.0m)
Debt / EBITDA = 0.94 (Net Debt 251.5m / EBITDA 267.0m)
Debt / FCF = 1.10 (Net Debt 251.5m / FCF TTM 229.0m)
Total Stockholder Equity = 879.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.26% (Net Income 174.8m / Total Assets 2.13b)
RoE = 19.89% (Net Income TTM 174.8m / Total Stockholder Equity 879.0m)
RoCE = 19.10% (EBIT 244.0m / Capital Employed (Equity 879.0m + L.T.Debt 398.1m))
RoIC = 10.90% (NOPAT 188.5m / Invested Capital 1.73b)
WACC = 5.93% (E(2.11b)/V(2.76b) * Re(6.74%) + D(655.7m)/V(2.76b) * Rd(4.31%) * (1-Tc(0.23)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -20.83 | Cagr: -1.00%
[DCF] Terminal Value 75.55% ; FCFF base≈228.2m ; Y1≈230.8m ; Y5≈248.0m
[DCF] Fair Price = 44.30 (EV 3.85b - Net Debt 251.5m = Equity 3.60b / Shares 81.3m; r=8.35% [WACC [floored]]; 5y FCF grow 0.87% → 2.50% )
EPS Correlation: 91.61 | EPS CAGR: 26.72% | SUE: 0.55 | # QB: 0
Revenue Correlation: -82.75 | Revenue CAGR: -1.74% | SUE: 1.64 | # QB: 2
EPS current Quarter (2026-09-30): EPS=0.65 | Chg30d=-2.71% | Revisions=-30% | Analysts=7
EPS current Year (2026-12-31): EPS=2.35 | Chg30d=+3.17% | Revisions=+62% | GrowthEPS=+15.1% | GrowthRev=+2.5%
EPS next Year (2027-12-31): EPS=2.44 | Chg30d=+3.39% | Revisions=+57% | GrowthEPS=+3.9% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: +32% (up=11, down=5)